Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1749630 | 0.80 | ADH1C (0.34) | SMN1; SMN2 | |
| SCHEMBL9646368 | 0.79 | — | — | |
| SCHEMBL3710483 | 0.78 | ADH1A (0.38) | SMN1; SMN2 | |
| SCHEMBL2754289 | 0.78 | MAPT (0.33) | MAPTRAB9A | |
| SCHEMBL8506062 | 0.76 | — | — | |
| SCHEMBL4696055 | 0.76 | MAPT (0.35) | SMN1; SMN2TSHRALDH1A1NPC1MAPT | |
| SCHEMBL14085013 | 0.73 | ADH1C (0.34) | POLBALDH1A1NPC1 | |
| SCHEMBL4763981 | 0.72 | SMN1; SMN2 (0.39) | SMN1; SMN2POLBHTTTSHRALDH1A1 | |
| SCHEMBL27731902 | 0.71 | TSHR (0.38) | SMN1; SMN2POLBHTTTSHRALDH1A1 | |
| SCHEMBL8944585 | 0.70 | LMNA (0.42) | SMN1; SMN2POLBHTTTSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1713806-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2013-05-08 | — | — | EP | claimed |
| US-8344018-B2 | Oxindolyl inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2013-01-01 | — | — | US | claimed |
| US-8134000-B2 | Imidazolyl pyrimidine inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-03-13 | — | — | US | claimed |
| US-8124764-B2 | Fused heterocyclyc inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-02-28 | — | — | US | claimed |
| JP-2011528039-A | — | — | 2011-11-10 | — | — | JP | claimed |
| JP-2011528040-A | — | — | 2011-11-10 | — | — | JP | claimed |
| US-7968557-B2 | Diseases with abnormal activation of the Abl, BCR-Abl, Bmx, CSK, TrkB, FGFR3, Fes, Lck, B-RAF, C-RAF, MKK6, alpha and beta SAPK2 kinases; antiproliferative; pyrrolo[2,3-d]pyrimidine-7-carboxylic acid [3-phenylcarbamoyl-phenyl]-amides and pyrrolo[3,2-c]pyridine analogs | NOVARTIS AG (CH) | 2011-06-28 | — | — | US | claimed |
| US-20110135594-A1 | OXINDOLYL INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2011-06-09 | — | — | US | claimed |
| EP-2303841-A1 | OXINDOLYL INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-04-06 | — | — | EP | claimed |
| EP-2303881-A2 | FUSED HETEROCYCLYC INHIBITORS OF HISTONE DEACETYLASE AND/OR CYCLIN-DEPENDENT KINASES | GILEAD SCIENCES, INC. (US) | 2011-04-06 | — | — | EP | claimed |
| WO-2010009166-A1 | OXINDOLYL INHIBITOR COMPOUNDS | GILEAD COLORADO, INC. (US) | 2010-01-21 | — | — | WO | claimed |
| WO-2010009139-A2 | IMIDAZOLYL PYRIMIDINE INHIBITOR COMPOUNDS | GILEAD COLORADO, INC. (US) | 2010-01-21 | — | — | WO | claimed |
| WO-2010009155-A2 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | GILEAD COLORADO, INC. (US) | 2010-01-21 | — | — | WO | claimed |
| US-20100009990-A1 | IMIDAZOLYL PYRIMIDINE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2010-01-14 | — | — | US | claimed |
| US-20090005374-A1 | IMIDAZOPYRIDINYL THIAZOLYL HISTONE DEACETYLASE INHIBITORS | GILEAD SCIENCES, INC. | 2009-01-01 | — | — | US | claimed |
| WO-2009002534-A1 | IMIDAZOPYRIDINYL THIAZOLYL HISTONE DEACETYLASE INHIBITORS | GILEAD COLORADO, INC. (US) | 2008-12-31 | — | — | WO | claimed |
| US-20070225306-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2007-09-27 | — | — | US | claimed |
| EP-1713806-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2006-10-25 | — | — | EP | claimed |
| WO-2005107760-A1 | COMPOUNDS AND COMPOSITIONS AS INDUCERS OF KERATINOCYTE DIFFERENTIATION | IRM LLC (BM) | 2005-11-17 | — | — | WO | claimed |
| WO-2005080393-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2005-09-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009990-A1 | IMIDAZOLYL PYRIMIDINE INHIBITOR COMPOUNDS | HDAC1, CDK9, CDK2 | SMN1; SMN2 2117/4885POLB 197/4885HTT 2269/4885 |
| US-20090005374-A1 | IMIDAZOPYRIDINYL THIAZOLYL HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC8, HDAC5 | SMN1; SMN2 2119/4885POLB 289/4885HTT 1725/4885 |
| US-20070225306-A1 | Compounds and Compositions as Protein Kinase Inhibitors | ABL1, PDGFRA, PDGFRB | SMN1; SMN2 3425/4885POLB 2554/4885HTT 1396/4885 |
| US-20110135594-A1 | OXINDOLYL INHIBITOR COMPOUNDS | HDAC1, HDAC8, HDAC11 | SMN1; SMN2 3496/4885POLB 428/4885HTT 2298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.